Contact
searchSearch
HMP Global

FDA Alerts

Atopic dermatitis
FDA Alerts
FDA Approves Tapinarof Cream 1% for Atopic Dermatitis in Adults and Children
12/16/2024
Organon’s VTAMA cream, 1%, offers a steroid-free solution for patients 2 years and older with moderate-to-severe atopic dermatitis, featuring powerful skin clearance and rapid itch relief.
Organon’s VTAMA cream, 1%, offers a steroid-free solution for patients 2 years and older with moderate-to-severe atopic dermatitis, featuring powerful skin clearance and rapid itch relief.
Organon’s VTAMA cream, 1%,...
12/16/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
Nemolizumab Receives FDA Approval for Moderate-to-Severe Atopic Dermatitis
12/16/2024
Galderma’s Nemluvio (nemolizumab) offers a novel treatment targeting IL-31 receptor alpha, addressing itch and inflammation in atopic dermatitis.
Galderma’s Nemluvio (nemolizumab) offers a novel treatment targeting IL-31 receptor alpha, addressing itch and inflammation in atopic dermatitis.
Galderma’s Nemluvio...
12/16/2024
The Dermatologist
Face
FDA Alerts
Bimekizumab FDA Approved for Moderate to Severe Hidradenitis Suppurativa
11/20/2024
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug Administration has approved UCB’s BIMZELX (bimekizumab-bkzx) for the treatment of adults with moderate to severe hidradenitis suppurativa.
The US Food and Drug...
11/20/2024
The Dermatologist
PsA
FDA Alerts
Bimekizumab FDA Approved for the Treatment of Psoriatic Arthritis
09/24/2024
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug Administration (FDA) has approved UCB’s BIMZELX (bimekizumab-bkzx), an IL-17A and IL-17F inhibitor, for the treatment of adults with active psoriatic arthritis (PsA).
The US Food and Drug...
09/24/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Lebrikizumab FDA Approved for Moderate to Severe Atopic Dermatitis in Adults and Children
09/16/2024
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug Administration has approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz), an IL-13 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and children.
The US Food and Drug...
09/16/2024
The Dermatologist
Alopecia Areata, blad head
FDA Alerts
Deuruxolitinib FDA Approved for Severe Alopecia Areata in Adults
07/30/2024
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved...
07/30/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.15% for Treatment of Atopic Dermatitis in Adults and Children Aged 6 and Older
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug...
07/09/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
Actinic Keratosis
FDA Alerts
FDA Approves Almirall’s Klisyri for Expanded Treatment Area of Actinic Keratosis
06/11/2024
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug...
06/11/2024
The Dermatologist
Atopic Derm
FDA Alerts
Dupixent Receives Expanded FDA Approval for Atopic Dermatitis with Moderate to Severe Hand and Foot Involvement
01/19/2024
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an...
01/19/2024
The Dermatologist
Nov/Dec 2024 Cover

Current Issue

December 2024
Volume 32
Issue 8
Current Issue
Issue Archive

Popular Articles

NEA Approved Features
JAK inhibitors for Atopic Dermatitis – STAT!
12/04/2018
JAK inhibitors appear to be effective for the treatment of AD, and this class of medications will influence the current paradigm of AD management.
JAK inhibitors appear to be effective for the treatment of AD, and this class of medications will influence the current paradigm of AD management.
JAK inhibitors appear to be...
12/04/2018
The Dermatologist
Spotlight
Spotlight On: Norman Goldstein, MD
10/09/2012
In dermatology, we are fortunate to have many insightful practitioners and great teachers and mentors. Some are bright stars in our special universe – others unsung heroes. All of these colleagues have much to share from wisdom to humor to...
In dermatology, we are fortunate to have many insightful practitioners and great teachers and mentors. Some are bright stars in our special universe – others unsung heroes. All of these colleagues have much to share from wisdom to humor to...
In dermatology, we are fortunate...
10/09/2012
The Dermatologist
NPF Endorsed Features
Inside the New Psoriasis Guidelines, Part I
05/01/2019
Recent updates address the latest evidence on the safety and efficacy of biologics.
Recent updates address the latest evidence on the safety and efficacy of biologics.
Recent updates address the...
05/01/2019
The Dermatologist
Cover Story
Best Clinical Practices in Laser Tattoo Removal
07/09/2012
The ability to remove tattoo ink safely, efficiently and with minimal side effects has improved significantly in the past decade. This article briefly discusses older, now obsolete methods of tattoo removal and current modalities used to...
The ability to remove tattoo ink safely, efficiently and with minimal side effects has improved significantly in the past decade. This article briefly discusses older, now obsolete methods of tattoo removal and current modalities used to...
The ability to remove tattoo ink...
07/09/2012
The Dermatologist
Propionibacterium acnes Abscess
12/11/2019
A 76-year-old woman presented with a 3-day history of a worsening lesion on her right cheek. The area had become reddened and painful. She had no fever, chills, or other constitutional symptoms.
A 76-year-old woman presented with a 3-day history of a worsening lesion on her right cheek. The area had become reddened and painful. She had no fever, chills, or other constitutional symptoms.
A 76-year-old woman presented...
12/11/2019
The Dermatologist

Subscribe

The Dermatologist Newsletter

Latest Quizzes and Trivia

Atopic Dermatitis + Eczema + Itch + Rash + Legs + Elbow + Knee
Quiz
Atopic Dermatitis and JAK Inhibitors
12/14/2024
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
1. How do JAK inhibitors differ from traditional immunosuppressant treatments for atopic dermatitis?a) They work extracellularly, directly blocking cytokines.b) They target inflammation at the intracellular level and are more selective.c)...
1. How do JAK inhibitors differ...
12/14/2024
The Dermatologist
Illustration of JAK1 Protein
Quiz
Test Your Knowledge: The Immunology of JAK Inhibitors
12/05/2024
12/05/2024
The Dermatologist
Gil Yosipovitch, MD
Quiz
Long-Term Efficacy of Dupilumab for Prurigo Nodularis
12/05/2024
What future research is needed to better understand the long-term efficacy of dupilumab for prurigo nodularis?
What future research is needed to better understand the long-term efficacy of dupilumab for prurigo nodularis?
What future research is needed...
12/05/2024
The Dermatologist
Atopic dermatitis
Quiz
Pediatric Atopic Dermatitis Management
11/11/2024
1. What alternative therapies does Dr Lisa Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr...
1. What alternative therapies does Dr Lisa Swanson suggest for children who have difficulty adhering to topical treatment regimens?a) Antibioticsb) Injectable or oral medicationsc) UV light therapyd) Homeopathic remedies2. According to Dr...
1. What alternative therapies...
11/11/2024
The Dermatologist
Illustration of a T cell
QUIZ
Test Your Knowledge: The Immunology of Alopecia Areata
11/04/2024
11/04/2024
The Dermatologist
psoriasis
Quiz
Long-Term Safety of Risankizumab
10/18/2024
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings regarding the long-term safety of risankizumab?
What were the primary findings...
10/18/2024
The Dermatologist
Brain
Quiz
Barriers to Mental Health Support
10/10/2024
What was the first barrier to mental health support for patients with atopic dermatitis identified in the NEA survey?
What was the first barrier to mental health support for patients with atopic dermatitis identified in the NEA survey?
What was the first barrier to...
10/10/2024
The Dermatologist
AD
Quiz
QUIZ: Psoriasis and Atopic Dermatitis: Nonsteroidal Topical Therapies
09/15/2024
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein...
09/15/2024
The Dermatologist
psoriasis
Quiz
QUIZ: Topical PDE-4 Inhibitors For Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
08/10/2024
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola...
08/10/2024
The Dermatologist
contact dermtitis + Neck + Eczema + rash
Quiz
QUIZ: Patient Experiences in Contact Dermatitis and Patch Testing
07/14/2024
What is a common challenge for patients during the patch testing week?
What is a common challenge for patients during the patch testing week?
What is a common challenge for...
07/14/2024
The Dermatologist

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use